Anavex Life Sciences Corp (NASDAQ:AVXL) said pre-clinical data from its candidate ANAVEX 3-71 reinforced its belief it could be a treatment for the cognitive disease Alzheimer's.
The findings, which were from studies on rats, were presented at the 14th international symposium of advances in Alzheimer's Therapy (AAT) from March 9-12.
The firm said there was a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation when ANAVEX 3-71 had been administered.
Professor Claudio Cuello of McGill University, Montreal, Canada, the main author of the study, said: "The data from this study further validates the belief that ANAVEX 3-71 may have significant utility in the treatment of Alzheimer’s disease.
"This study examined potential long-term effect of the compound following a five-week hiatus from dosing, which suggests the potential for disease modification – something we have not often seen."
Chief executive of Anavex Christopher U. Missling added: "This body of data of ANAVEX 3-71, in addition to our clinical candidate, ANAVEX 2-73 suggests that our approach of targeting the complex pathology of Alzheimer’s disease further upstream may have the potential to address the areas of unmet need for individuals living with this disease."
The firm is developing therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer.
Anavex’s lead drug candidate, ANAVEX 2-73 is currently in a Phase 2a clinical trial for Alzheimer’s.